aphidicolin glycinate has been researched along with Ovarian Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cysyk, R; Hamilton, TC; Harrison, SD; Moyer, JD; O'Dwyer, PJ; Plowman, J; Suffness, M | 1 |
| Cavalli, F; D'Incalci, M; Damia, G; Davoli, E; Sessa, C; Tagliabue, G; Zucchetti, M | 1 |
| Dempke, WC; Fichtinger-Schepman, AM; Hill, BT; Shellard, SA | 1 |
3 other study(ies) available for aphidicolin glycinate and Ovarian Neoplasms
| Article | Year |
|---|---|
Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Cisplatin; Disease Models, Animal; DNA Repair; DNA-Directed DNA Polymerase; Drug Administration Schedule; Drug Resistance; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Ovarian Neoplasms | 1994 |
Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Cell Line; Cisplatin; Drug Administration Schedule; Drug Resistance; Drug Synergism; Female; Half-Life; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Ovarian Neoplasms | 1992 |
Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
Topics: Antibiotics, Antineoplastic; Aphidicolin; Cisplatin; Diterpenes; DNA; DNA Damage; DNA Polymerase II; DNA Repair; Female; Guanine; Humans; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured | 1991 |